Business Description
Alk-Abello AS
NAICS : 325412
SIC : 2834
ISIN : DK0061802139
Share Class Description:
FRA:4AJ0: Class BDescription
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.43 | |||||
| Interest Coverage | 131.57 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 12.18 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 33.7 | |||||
| 3-Year EPS without NRI Growth Rate | 168.2 | |||||
| 3-Year FCF Growth Rate | 53.6 | |||||
| 3-Year Book Growth Rate | 11.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 43.06 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.19 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.2 | |||||
| 9-Day RSI | 28.68 | |||||
| 14-Day RSI | 33.12 | |||||
| 6-1 Month Momentum % | 8.29 | |||||
| 12-1 Month Momentum % | 115.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.36 | |||||
| Days Inventory | 281.71 | |||||
| Days Sales Outstanding | 59.18 | |||||
| Days Payable | 26.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | 0.26 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.42 | |||||
| Operating Margin % | 17.78 | |||||
| Net Margin % | 13.32 | |||||
| FCF Margin % | 13.98 | |||||
| ROE % | 15.28 | |||||
| ROA % | 10.27 | |||||
| ROIC % | 12.71 | |||||
| 3-Year ROIIC % | 44.32 | |||||
| ROC (Joel Greenblatt) % | 25.28 | |||||
| ROCE % | 16.89 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 50.26 | |||||
| Forward PE Ratio | 27.79 | |||||
| PE Ratio without NRI | 50.26 | |||||
| Shiller PE Ratio | 184.34 | |||||
| Price-to-Owner-Earnings | 43.73 | |||||
| PEG Ratio | 1.21 | |||||
| PS Ratio | 6.78 | |||||
| PB Ratio | 7.01 | |||||
| Price-to-Tangible-Book | 8.37 | |||||
| Price-to-Free-Cash-Flow | 48.37 | |||||
| Price-to-Operating-Cash-Flow | 33.56 | |||||
| EV-to-EBIT | 37.41 | |||||
| EV-to-EBITDA | 29.27 | |||||
| EV-to-Revenue | 6.67 | |||||
| EV-to-FCF | 47.75 | |||||
| Price-to-Projected-FCF | 6.02 | |||||
| Price-to-Median-PS-Value | 1.56 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.02 | |||||
| Price-to-Graham-Number | 4.33 | |||||
| Price-to-Net-Current-Asset-Value | 36.42 | |||||
| Earnings Yield (Greenblatt) % | 2.67 | |||||
| FCF Yield % | 2.1 | |||||
| Forward Rate of Return (Yacktman) % | 20.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alk-Abello AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 694.582 | ||
| EPS (TTM) (€) | 0.416 | ||
| Beta | 1.16 | ||
| Volatility % | 36.24 | ||
| 14-Day RSI | 33.12 | ||
| 14-Day ATR (€) | 0.29569 | ||
| 20-Day SMA (€) | 21.949 | ||
| 12-1 Month Momentum % | 115.53 | ||
| 52-Week Range (€) | 10.24 - 24.56 | ||
| Shares Outstanding (Mil) | 221.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alk-Abello AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alk-Abello AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alk-Abello AS Frequently Asked Questions
What is Alk-Abello AS(FRA:4AJ0)'s stock price today?
The current price of FRA:4AJ0 is €20.76. The 52 week high of FRA:4AJ0 is €24.56 and 52 week low is €10.24.
When is next earnings date of Alk-Abello AS(FRA:4AJ0)?
The next earnings date of Alk-Abello AS(FRA:4AJ0) is 2024-11-14.
Does Alk-Abello AS(FRA:4AJ0) pay dividends? If so, how much?
Alk-Abello AS(FRA:4AJ0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers